AI
Wednesday, January 25, 2012 12:25:10 PM
2/1/12 Webcast of QGEN Fourth Quarter and Year End 2011 Financial Results Call Set for February 1, 2012
Press Release: QIAGEN N.V. – Tue, Jan 24, 2012 9:10 AM EST
Email
Print
Companies:
Qiagen NVQIAGEN NV
RELATED QUOTES
Symbol Price Change
QGEN 16.33 +0.64
VENLO, Netherlands, Jan. 24, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN - News) today announced the Webcast of its fourth quarter and year-end 2011 financial results call. The Webcast will take place at 9:30 a.m. ET on Wednesday, February 1, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
What: Webcast of QIAGEN's fourth quarter and year-end 2011 financial results call
When: 9:30 a.m. ET on February 1
Where: The Webcast is accessible at www.qiagen.com/goto/ConferenceCall
How: Log on to the Web at the address above
The corresponding presentation slides will be available for download in the investor relations section of QIAGEN's Web site at www.qiagen.com/goto/ConferenceCall.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
The QIAGEN N.V. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3692
Contact:
QIAGEN N.V.
ir@qiagen.com
phone +49 2103 2911709
Press Release: QIAGEN N.V. – Tue, Jan 24, 2012 9:10 AM EST
Companies:
Qiagen NVQIAGEN NV
RELATED QUOTES
Symbol Price Change
QGEN 16.33 +0.64
VENLO, Netherlands, Jan. 24, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN - News) today announced the Webcast of its fourth quarter and year-end 2011 financial results call. The Webcast will take place at 9:30 a.m. ET on Wednesday, February 1, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
What: Webcast of QIAGEN's fourth quarter and year-end 2011 financial results call
When: 9:30 a.m. ET on February 1
Where: The Webcast is accessible at www.qiagen.com/goto/ConferenceCall
How: Log on to the Web at the address above
The corresponding presentation slides will be available for download in the investor relations section of QIAGEN's Web site at www.qiagen.com/goto/ConferenceCall.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
The QIAGEN N.V. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3692
Contact:
QIAGEN N.V.
ir@qiagen.com
phone +49 2103 2911709
***All my posts are purely my opinion. Please do your own DD & never invest in a stock you can not afford to lose money on.
